What should I avoid while taking Ergotamine tartrate 2mg sublingual tablets sugar free?

Take with or without food. The absorption is unaffected by food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Ergotamine tartrate 2mg sublingual tablets sugar free?

Ergotamine tartrate 2mg sublingual tablets sugar free is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ergotamine tartrate 2mg sublingual tablets sugar free?

Ergotamine tartrate 2mg sublingual tablets sugar free is the generic name. It is available under brand names including: Ergomar 2mg sublingual tablets sugar free. (Source: NHS dm+d — Actual Medicinal Products)

Ergotamine tartrate 2mg sublingual tablets sugar free

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

2mg

Oral

A vasoconstrictor found in ergot of Central Europe.

Active ingredients:

Ergotamine

Formulation:

Sugar-free

Does not contain sugar — suitable for diabetic patients

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N02CA02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ergotamine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ergotamine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

Search EudraVigilance database

Browse substances A–Z in the European adverse reaction database

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ergotamine on the MHRA register

Ergomar 2mg sublingual tablets sugar free

Imported (United States)

None

Imported

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Therapeutically similar medicines

5 similar

Tablets & capsules

(3)

Methysergide 1mg tablets

Tablet

1mg

Same therapeutic group

Ergotamine 1mg / Caffeine 100mg tablets

Tablet

1mg

Same therapeutic group

Generic Migril tablets

Tablet

Same therapeutic group

Injectables

(1)

Dihydroergotamine 1mg/1ml solution for injection ampoules

Injection

1mg/1ml

Same therapeutic group

Other

(1)

Ergotamine tartrate 2mg / Caffeine 100mg suppositories

Other

2mg

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Guidelines from the National Institute for Health and Care Excellence

NICE clinical guidance(1)

Gastroparesis in adults: oral erythromycin (ESUOM13)

ESUOM13

Evidence summary

Updated Jun 2013

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42102911000001108

dm+d ID

42102911000001108

VTM (Virtual Therapeutic Moiety)

775816000

VMP (Virtual Medicinal Product)

42102911000001108

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N02CA02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 20 · 1926–2025

Sort

Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies

Giuseppe Roberto, Emanuel Raschi, Carlo Piccinni, et al.

Cephalalgia, 2014

Systematic review

Highly cited for its field

Cited by 159

Analgesics
Cardiovascular Diseases
Ergotamines

Ergotamine in the acute treatment of migraine: A review and European consensus

Peer Tfelt‐Hansen

Brain, 2000

Review

Highly cited for its field

Cited by 396

Ergotamine
Europe
Migraine Disorders

Ergotamine and Dihydroergotamine: History, Pharmacology, and Efficacy

Stephen D. Silberstein, Douglas C McCrory

Headache The Journal of Head and Face Pain, 2003

Review

Cited by 228

Dihydroergotamine
Ergotamine
Migraine Disorders

MECHANISM OF MIGRAINE HEADACHE AND ACTION OF ERGOTAMINE TARTRATE

J. Graham, H. Wolff

Journal of Nervous and Mental Disease, 1938

Highly cited for its field

Cited by 565

Iatrogenic arterial aneurysm associated with ergotamine therapy.

M Pajewski, David Modai, J Wisgarten, et al.

PubMed, 1981

Highly cited for its field

Cited by 264

Aneurysm
Ergotamine
Ergotamines

ON A NEW AEROBIC METABOLITE WHOSE PRODUCTION BY BRAIN IS INHIBITED BY APOMORPHINE, EMETINE, ERGOTAMINE, EPINEPHRINE, AND MENADIONE

Henry I. Kohn, MARGARET LIVERSEDGE

Journal of Pharmacology and Experimental Therapeutics, 1944

Cited by 235

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann, et al.

European Neuropsychopharmacology, 2016

Highly cited for its field

Cited by 148

Behavior Rating Scale
Buspirone
Consciousness Disorders

Ergotamine and dihydroergotamine: A review

Marcelo E. Bigal, Stewart J. Tepper

Current Pain and Headache Reports, 2003

Review

Cited by 89

Dihydroergotamine
Ergotamine
Migraine Disorders

Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan – Basic Science in Relation to Migraine Treatment

Carl Dahlöf, Antoinette MaassenVanDenBrink

Headache The Journal of Head and Face Pain, 2012

Review

Cited by 85

Dihydroergotamine
Ergotamine
Methysergide

ROLE OF SOME BIOGENIC SUBSTANCES IN MIGRAINE AND RELEVANT MECHANISM IN ANTIMIGRAINE ACTION OF ERGOTAMINE‐STUDIES IN AN EXPERIMENTAL MODEL FOR MIGRAINE

P. Saxena, GEERTRUDE M. VLAAM‐SCHLUTER

Headache: The Journal of Head and Face Pain, 1974

Review

Highly cited for its field

Cited by 85

Adrenergic alpha-Antagonists
Aorta, Thoracic
Blood Pressure

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

27 found

Half-life

2 hours

Mechanism

Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of…

Food interactions

1 warning

Human targets

14 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

The bioavailability of sublingually administered ergotamine has not been determined.

Half-life

2 hours

2 hours

Metabolism

90%

Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Small molecule

About this compound

A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.

Properties:

solid

Avg. mass: 581.66 Da

DrugBank indication

For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".

Also known as(98)

(5'α)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione

12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione

12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione

Ergotamin

Ergotamina

Ergotamine

Ergotaminum

5-HT-1D

Molecular properties(19)

Drug interactions(1774)

Known interactions with other medications. Always consult a healthcare professional.

Armodafinil

Moderate

DB06413

The metabolism of Ergotamine can be increased when combined with Armodafinil.

Check this interaction

Carboprost tromethamine

Moderate

DB00429

Carboprost tromethamine may increase the uterotonic activities of Ergotamine.

Check this interaction

Valsartan

Moderate

DB00177

Ergotamine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Ergotamine may decrease the antihypertensive activities of Ramipril.

Check this interaction

Remikiren

Moderate

DB00212

Ergotamine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Torasemide

Moderate

DB00214

Ergotamine may decrease the antihypertensive activities of Torasemide.

Check this interaction

Guanadrel

Moderate

DB00226

Ergotamine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Ergotamine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Chlorthalidone

Moderate

DB00310

Ergotamine may decrease the antihypertensive activities of Chlorthalidone.

Check this interaction

Nitroprusside

Moderate

DB00325

Ergotamine may decrease the antihypertensive activities of Nitroprusside.

Check this interaction

Minoxidil

Moderate

DB00350

Ergotamine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Treprostinil

Moderate

DB00374

Ergotamine may decrease the antihypertensive activities of Treprostinil.

Check this interaction

Bendroflumethiazide

Moderate

DB00436

Ergotamine may decrease the antihypertensive activities of Bendroflumethiazide.

Check this interaction

Fosinopril

Moderate

DB00492

Ergotamine may decrease the antihypertensive activities of Fosinopril.

Check this interaction

Trandolapril

Moderate

DB00519

Ergotamine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Metolazone

Moderate

DB00524

Ergotamine may decrease the antihypertensive activities of Metolazone.

Check this interaction

Benazepril

Moderate

DB00542

Ergotamine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Cyclothiazide

Moderate

DB00606

Ergotamine may decrease the antihypertensive activities of Cyclothiazide.

Check this interaction

Candoxatril

Moderate

DB00616

Ergotamine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Mecamylamine

Moderate

DB00657

Ergotamine may decrease the antihypertensive activities of Mecamylamine.

Check this interaction

Moexipril

Moderate

DB00691

Ergotamine may decrease the antihypertensive activities of Moexipril.

Check this interaction

Lisinopril

Moderate

DB00722

Ergotamine may decrease the antihypertensive activities of Lisinopril.

Check this interaction

Hydroflumethiazide

Moderate

DB00774

Ergotamine may decrease the antihypertensive activities of Hydroflumethiazide.

Check this interaction

Cryptenamine

Moderate

DB00785

Ergotamine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Perindopril

Moderate

DB00790

Ergotamine may decrease the antihypertensive activities of Perindopril.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Ergotamine may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Fenoldopam

Moderate

DB00800

Ergotamine may decrease the antihypertensive activities of Fenoldopam.

Check this interaction

Eprosartan

Moderate

DB00876

Ergotamine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Chlorothiazide

Moderate

DB00880

Ergotamine may decrease the antihypertensive activities of Chlorothiazide.

Check this interaction

Quinapril

Moderate

DB00881

Ergotamine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Ergotamine may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Hydrochlorothiazide

Moderate

DB00999

Ergotamine may decrease the antihypertensive activities of Hydrochlorothiazide.

Check this interaction

Trichlormethiazide

Moderate

DB01021

Ergotamine may decrease the antihypertensive activities of Trichlormethiazide.

Check this interaction

Deserpidine

Moderate

DB01089

Ergotamine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Ergotamine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Ergotamine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Diazoxide

Moderate

DB01119

The metabolism of Diazoxide can be decreased when combined with Ergotamine.

Check this interaction

Bretylium

Moderate

DB01158

Ergotamine may decrease the antihypertensive activities of Bretylium.

Check this interaction

Captopril

Moderate

DB01197

Ergotamine may decrease the antihypertensive activities of Captopril.

Check this interaction

Epoprostenol

Moderate

DB01240

Ergotamine may decrease the antihypertensive activities of Epoprostenol.

Check this interaction

Polythiazide

Moderate

DB01324

Ergotamine may decrease the antihypertensive activities of Polythiazide.

Check this interaction

Cilazapril

Moderate

DB01340

Ergotamine may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Ergotamine may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Ergotamine may decrease the antihypertensive activities of Spirapril.

Check this interaction

Tienilic acid

Moderate

DB04831

Ergotamine may decrease the antihypertensive activities of Tienilic acid.

Check this interaction

Diethylnorspermine

Moderate

DB06445

Ergotamine may decrease the antihypertensive activities of Diethylnorspermine.

Check this interaction

Temocapril

Moderate

DB08836

Ergotamine may decrease the antihypertensive activities of Temocapril.

Check this interaction

Nicorandil

Moderate

DB09220

Ergotamine may decrease the antihypertensive activities of Nicorandil.

Check this interaction

Rauwolfia serpentina root

Moderate

DB09363

Ergotamine may decrease the antihypertensive activities of Rauwolfia serpentina root.

Check this interaction

Enalaprilat

Moderate

DB09477

Ergotamine may decrease the antihypertensive activities of Enalaprilat.

Check this interaction

Showing 50 of 1774 interactions

Food & lifestyle interactions

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

Signs of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion.

How it works

Mechanism of action

Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT_1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT_1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.

Pharmacodynamics

Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

The bioavailability of sublingually administered ergotamine has not been determined.

Half-life

2 hours

Metabolism

Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile.

Drug targets(14)

Proteins and enzymes this drug interacts with in the body

5-hydroxytryptamine receptor 1D

BE0000659

HTR1D

agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1565658 PMID:1652050 PMID:33762731

HTR1D is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:33762731
Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity .
PMID:18476671 PMID:20945968
May also play a role in regulating the release of other neurotransmitters .
PMID:18476671 PMID:20945968
May play a role in vasoconstriction PMID:18476671 PMID:20945968

5-hydroxytryptamine receptor 1B

BE0000797

HTR1B

agonist

Specific functionG protein-coupled serotonin receptor activity

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD) .
PMID:23519210 PMID:23519215 PMID:29925951

Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase .
PMID:10452531 PMID:1315531 PMID:1328844 PMID:1348246 PMID:1351684 PMID:1559993 PMID:1565658 PMID:1610347 PMID:23519210 PMID:23519215 PMID:29925951 PMID:8218242

HTR1B is coupled to G(i)/G(o) G alpha proteins and mediates inhibitory neurotransmission by inhibiting adenylate cyclase activity .
PMID:29925951 PMID:35610220
Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:29925951
Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior .
PMID:18476671 PMID:20945968
Besides, plays a role in vasoconstriction of cerebral arteries PMID:15853772

5-hydroxytryptamine receptor 2A

BE0000451

HTR2A

agonist

Specific function1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding

Cellular location

Cell membrane

General function & pharmacology

G-protein coupled receptor for 5-hydroxytryptamine (serotonin) .
PMID:1330647 PMID:18703043 PMID:19057895 PMID:21645528 PMID:22300836 PMID:35084960 PMID:38552625

Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD) .
PMID:28129538 PMID:35084960
Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors .
PMID:28129538 PMID:35084960
HTR2A is coupled to G(q)/G(11) G alpha proteins and activates phospholipase C-beta, releasing diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) second messengers that modulate the activity of phosphatidylinositol 3-kinase and promote the release of Ca(2+) ions from intracellular stores, respectively .
PMID:18703043 PMID:28129538 PMID:35084960

Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways .
PMID:28129538 PMID:35084960
Affects neural activity, perception, cognition and mood .
PMID:18297054
Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction (By similarity)

Alpha-1A adrenergic receptor

BE0000501

ADRA1A

partial agonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Nucleus membrane

General function & pharmacology

This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes

Alpha-1B adrenergic receptor

BE0000575

ADRA1B

partial agonist

Specific functionalpha1-adrenergic receptor activity

Cellular location

Nucleus membrane

General function & pharmacology

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Scientific references(2)

Tfelt-Hansen P., Saxena P.R., Dahlof C., Pascual J., Lainez M., Henry P., Diener H., Schoenen J., Ferrari M.D., Goadsby P.J.

Ergotamine in the acute treatment of migraine: A review and European consensus.

Brain

2000123(1):9-18. doi: 10.1093/brain/123.1.9

PMID: 10611116 DOI: 10.1093/brain/123.1.9

Schardl C.L., Panaccione D.G., Tudzynski P.

Chapter 2 Ergot Alkaloids – Biology and Molecular Biology. The Alkaloids: Chemistry and Biology. 2006;:45-86.

doi: 10

1016/s1099-4831(06)63002-2

PMID: 17133714 DOI: 10.1016/s1099-4831(06)63002-2

ATC classification(3 codes)

ATC N02CA02

ATC N02CA52

ATC N02CA72

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Ergotamine tartrate(DBSALT000979)

Experimental properties(3)

External resources(3)

RxList PDRhealth Drugs.com

Protein Data Bank entries(6)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ergotamine

DB00696

CAS number

113-15-5

UNII (FDA)

PR834Q503T

InChI Key (molecular fingerprint)

XCGSFFUVFURLIX-VFGNJEKYSA-N

Additional database identifiers

Drugs Product Database (DPD)

9252

Drugs Product Database (DPD)

11218

ChEBI

64318

PubChem Compound

8223

PubChem Substance

46507632

KEGG Compound

C07544

KEGG Drug

D07906

ChemSpider

7930

BindingDB

50027065

PharmGKB

PA164747651

PDB

ERM

Therapeutic Targets Database

DAP000141

Wikipedia

Ergotamine

ChEMBL

CHEMBL442

ZINC

ZINC000052955754

RxCUI

4025

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5289

GenAtlas

HTR1D

GeneCards

HTR1D

GenBank Gene Database

M89955

GenBank Protein Database

177772

IUPHAR

Guide to Pharmacology

UniProtKB

P28221

UniProt Accession

5HT1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5287

GenAtlas

HTR1B

GeneCards

HTR1B

GenBank Gene Database

D10995

GenBank Protein Database

219679

IUPHAR

Guide to Pharmacology

UniProtKB

P28222

UniProt Accession

5HT1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5293

GenAtlas

HTR2A

GeneCards

HTR2A

GenBank Gene Database

S42168

GenBank Protein Database

36431

IUPHAR

Guide to Pharmacology

UniProtKB

P28223

UniProt Accession

5HT2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:277

GenAtlas

ADRA1A

GeneCards

ADRA1A

GenBank Gene Database

D25235

GenBank Protein Database

433201

IUPHAR

Guide to Pharmacology

UniProtKB

P35348

UniProt Accession

ADA1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:278

GenAtlas

ADRA1B

GeneCards

ADRA1B

GenBank Gene Database

M99589

IUPHAR

Guide to Pharmacology

UniProtKB

P35368

UniProt Accession

ADA1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:280

GenAtlas

ADRA1D

GeneCards

ADRA1D

GenBank Gene Database

M76446

GenBank Protein Database

177807

IUPHAR

Guide to Pharmacology

UniProtKB

P25100

UniProt Accession

ADA1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:281

GenAtlas

ADRA2A

GeneCards

ADRA2A

GenBank Gene Database

M23533

GenBank Protein Database

178196

IUPHAR

Guide to Pharmacology

UniProtKB

P08913

UniProt Accession

ADA2A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5292

GenAtlas

HTR1F

GeneCards

HTR1F

GenBank Gene Database

L05597

GenBank Protein Database

307420

IUPHAR

Guide to Pharmacology

UniProtKB

P30939

UniProt Accession

5HT1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5295

GenAtlas

HTR2C

GeneCards

HTR2C

GenBank Gene Database

M81778

GenBank Protein Database

338028

IUPHAR

Guide to Pharmacology

UniProtKB

P28335

UniProt Accession

5HT2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5294

GenAtlas

HTR2B

GeneCards

HTR2B

GenBank Gene Database

X77307

GenBank Protein Database

475198

IUPHAR

Guide to Pharmacology

UniProtKB

P41595

UniProt Accession

5HT2B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:283

GenAtlas

ADRA2C

GeneCards

ADRA2C

GenBank Gene Database

J03853

GenBank Protein Database

178194

IUPHAR

Guide to Pharmacology

UniProtKB

P18825

UniProt Accession

ADA2C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(8 Mar 2026)

Structured knowledge from the free knowledge base

Q419186

Wikipedia article

chemical compound

Read on Wikipedia

WHO INN:ergotamine

International Nonproprietary Name

Research database identifiers

MeSH

D004878

ChEBI

CHEBI:64318

ATC classifications (Wikidata)

N02CA02

Linked open data from Wikidata (Q419186), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.

Source: Q419186CC0 1.0

Updated 1 day ago(5 Jul 2026)

Back to medicines

Ergotamine tartrate 2mg sublingual tablets sugar free

Safety monitoring data

Yellow Card reports

EudraVigilance

Tablets & capsules

Injectables

Other

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science
16

Chemical identifiers

Ergotamine

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Ergotamine tartrate 2mg sublingual tablets sugar free

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Tablets & capsules

Injectables

Other

NICE clinical guidance

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Metabolism

Clinical essentials

Pharmacology

Deep science16

Chemical identifiers

Ergotamine

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
16